Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations

 v2.3.0.11
Discontinued Operations
 6 Months Ended
Jun. 30, 2011
Discontinued Operations
2.
Discontinued Operations

We have reclassified all revenues and expenses related to discontinued operations of our Cardiosonix subsidiary for all periods presented.  We expect to continue to generate minimal revenues from sales of our remaining inventory and incur minimal expenses related to our blood flow measurement device business until a final shutdown of operations or a sale of the business unit is completed.  The following amounts have been segregated from continuing operations and included in discontinued operations in the consolidated statements of operations:

   
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2011
    
2010
    
2011
    
2010
  
                         
Net sales
   $ 11,395     $ 21,790     $ 43,960     $ 36,235  
Cost of goods sold
     1,360       5,227       3,986       11,616  
Gross profit
     10,035       16,563       39,974       24,619  
                                 
Operating expenses:
                                
Research and development
     1,859       10,557       17,292       10,808  
Selling, general and administrative
     8,050       6,660       15,554       26,522  
Total operating expenses
     9,879       17,217       32,846       37,330  
                                 
Other income (expense)
     (276 )     (63 )     (222 )     121  
                                 
Income (loss) from discontinued operations
   $ (120 )   $ (717 )   $ 6,906     $ (12,590 )